Related Experiment Video

Updated: Apr 23, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

7.7K

A polymorphism in HLA-G modifies statin benefit in asthma

D Naidoo1, A C Wu2, M H Brilliant3

  • 1Atherosclerosis Research, Children's Hospital Oakland Research Institute, Oakland, CA, USA.

The Pharmacogenomics Journal
|October 1, 2014
PubMed

Insights

Statins may improve asthma outcomes, but effects vary. A specific gene variant (rs1063320) influences how statins affect asthma by modulating microRNA binding to HLA-G, impacting treatment effectiveness.

Area of Science:

  • Immunogenetics
  • Pharmacogenomics
  • Respiratory Medicine

Background:

  • Statin therapy shows variable benefits for asthma patients.
  • The microRNA (mir)-152 family (mir-148a, mir-148b, mir-152) is linked to asthma.
  • MicroRNAs regulate HLA-G expression, and the rs1063320 single nucleotide polymorphism (SNP) in HLA-G influences miRNA binding and asthma risk.

Purpose of the Study:

  • To investigate the relationship between statins, microRNAs, HLA-G, and the rs1063320 SNP in asthma.
  • To determine if rs1063320 modifies statin efficacy in asthma management.

Main Methods:

  • Analysis of mir-148b and mir-152 expression in relation to statin use.
  • Assessment of HLA-G expression changes.
  • Genotyping for the rs1063320 SNP in asthma patients using statins.
  • Correlation of rs1063320 genotype with asthma exacerbation rates in statin users.

Main Results:

  • Statins were found to upregulate mir-148b and mir-152.
  • Statin effects on HLA-G expression were dependent on the rs1063320 genotype.
  • Individuals with the G minor allele of rs1063320 experienced fewer asthma exacerbations when using statins (P=0.03).

Conclusions:

  • The rs1063320 SNP modifies the impact of statin treatment on asthma.
  • This genetic variation may explain differences in statin efficacy for asthma management.

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
155
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
113
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.6K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K